Unknown

Dataset Information

0

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor.


ABSTRACT: Overexpression of ABCG2 remains a major impediment to successful cancer treatment, because ABCG2 functions as an efflux pump of chemotherapeutic agents and causes clinical multidrug resistance (MDR). Therefore, it is important to uncover effective modulators to circumvent ABCG2-mediated MDR in cancers. In this study, we reported that AZ-628, a RAF kinase inhibitor, effectively antagonizes ABCG2-mediated MDR in vitro. Our results showed that AZ-628 completely reversed ABCG2-mediated MDR at a non-toxic concentration (3 ?M) without affecting ABCB1-, ABCC1-, or ABCC10 mediated MDR. Further studies revealed that the reversal mechanism was by attenuating ABCG2-mediated efflux and increasing intracellular accumulation of ABCG2 substrate drugs. Moreover, AZ-628 stimulated ABCG2-associated ATPase activity in a concentration-dependent manner. Docking and molecular dynamics simulation analysis showed that AZ-628 binds to the same site as ABCG2 substrate drugs with higher score. Taken together, our studies indicate that AZ-628 could be used in combination chemotherapy against ABCG2-mediated MDR in cancers.

SUBMITTER: Wang JQ 

PROVIDER: S-EPMC7753047 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor.

Wang Jing-Quan JQ   Teng Qiu-Xu QX   Lei Zi-Ning ZN   Ji Ning N   Cui Qingbin Q   Fu Han H   Lin Lizhu L   Yang Dong-Hua DH   Fan Ying-Fang YF   Chen Zhe-Sheng ZS  

Frontiers in cell and developmental biology 20201208


Overexpression of ABCG2 remains a major impediment to successful cancer treatment, because ABCG2 functions as an efflux pump of chemotherapeutic agents and causes clinical multidrug resistance (MDR). Therefore, it is important to uncover effective modulators to circumvent ABCG2-mediated MDR in cancers. In this study, we reported that AZ-628, a RAF kinase inhibitor, effectively antagonizes ABCG2-mediated MDR <i>in vitro</i>. Our results showed that AZ-628 completely reversed ABCG2-mediated MDR at  ...[more]

Similar Datasets

| S-EPMC3854760 | biostudies-literature
| S-EPMC3949660 | biostudies-literature
| S-EPMC2878084 | biostudies-literature
| S-EPMC3443622 | biostudies-literature
| S-EPMC7016283 | biostudies-literature
| S-EPMC6718313 | biostudies-literature
| S-EPMC5960723 | biostudies-literature
| S-EPMC3480739 | biostudies-literature
| S-EPMC5392419 | biostudies-literature
| S-EPMC4027943 | biostudies-literature